Ocular Therapeutix宣布，其候选产品Axpaxli在湿痔疮相关性视网膜变性的SOL-R注册试验的入组将于本周结束，头条读数预计将于2026年1季度发布

2025-05-28 19:05

Enrollment for SOL-R, the largest retinal TKI trial to date, supports randomization of at least 555 subjects
SOL-1, Ocular's first registrational trial in wet AMD, completed randomization in December 2024 and retention remains exceptional as the trial continues on track for top-line readout in 1Q 2026
These two complementary trials are intended to form the basis of an NDA submission of AXPAXLI in wet AMD